Skip to main content

Advertisement

SpringerLink
Log in

Antifibrotic targets and therapy in HCV

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Great progress has been made over the past 20 years in elucidating the mechanisms of hepatic fibrogenesis. The recognition of the hepatic stellate cell as the fibrogenic cell of the liver, as well as the recognition of key cytokines involved in fibrogenesis, has facilitated the development of targeted Antifibrotic therapies. Patients with chronic hepatitis C and fibrosis may benefit from these novel Antifibrotic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556–562.

    Article  PubMed  CAS  Google Scholar 

  2. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.

    Article  PubMed  CAS  Google Scholar 

  3. Davis GL, Albright JE, Cook SF, et al.: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331–338.

    Article  PubMed  Google Scholar 

  4. Kweon YO, Goodman ZD, Dienstag JL, et al.: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749–755.

    Article  PubMed  CAS  Google Scholar 

  5. Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 123:1061–1069.

    Article  PubMed  CAS  Google Scholar 

  6. Issa R, Zhou X, Constandinou CM, et al.: Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795–1808. Discusses possible mechanisms for the regression of cirrhosis.

    Article  PubMed  CAS  Google Scholar 

  7. Albanis E, Friedman SL: Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001, 5:315–334.

    Article  PubMed  CAS  Google Scholar 

  8. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247–2250.

    Article  PubMed  CAS  Google Scholar 

  9. Pinzani M, Marra F: Cytokine receptors and signaling during stellate cell activation. Semin Liver Dis 2001, 21:397–416.

    Article  PubMed  CAS  Google Scholar 

  10. Pinzani M, Milani S, Grappone C, et al.: Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology 1994, 19:701–707.

    Article  PubMed  CAS  Google Scholar 

  11. Olaso E, Friedman SL: Molecular mechanisms of hepatic fibrogenesis. J Hepatol 1998, 29:836–847.

    Article  PubMed  CAS  Google Scholar 

  12. Bachem MG, Riess U, Melchio R, et al.: Transforming growth factors (TGF alpha and TGF beta 2) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. FEBS Lett 1989, 257:134–137.

    Article  PubMed  CAS  Google Scholar 

  13. Dooley S, Delvoux B, Lahme B, et al.: Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000, 31:1094–1106.

    Article  PubMed  CAS  Google Scholar 

  14. Friedman SL, Yamasaki G, Wong L: Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J Biol Chem 1994, 269:10551–10558.

    PubMed  CAS  Google Scholar 

  15. Rockey DC: Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001, 21:337–350.

    Article  PubMed  CAS  Google Scholar 

  16. Racine-Samson L, Rockey DC, Bissell DM: The role of alpha-beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 1997, 272:30911–30917.

    Article  PubMed  CAS  Google Scholar 

  17. Rockey DC, Chung JJ: Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995, 95:1199–1206.

    PubMed  CAS  Google Scholar 

  18. Gupta TK, Toruner M, Chung MK, et al.: Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998, 28:926–931.

    Article  PubMed  CAS  Google Scholar 

  19. Gupta TK, Toruner M, Groszmann RJ: Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide. Digestion 1998, 59:413–415.

    Article  PubMed  CAS  Google Scholar 

  20. Groszmann RJ: Nitric oxide and hemodynamic impairments. Digestion 1998, 59(suppl 2):6–7.

    Article  PubMed  CAS  Google Scholar 

  21. Benyon D, Arthur MJP: Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001, 21:373–384.

    Article  PubMed  CAS  Google Scholar 

  22. Iredale JP: Stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001, 21:427–436.

    Article  PubMed  CAS  Google Scholar 

  23. Iredale JP, Benyon RC, Pickering J, et al.: Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538–549.

    PubMed  CAS  Google Scholar 

  24. Wang SC, Tsukamoto H, Rippe RA, et al.: Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 1998, 273:302–308.

    Article  PubMed  CAS  Google Scholar 

  25. Thompson K, Maltby J, Fallowfield J, et al.: Interleukin- 10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998, 28:1597–1606.

    Article  PubMed  CAS  Google Scholar 

  26. Gentilini M, Marra F, Gentilini P, et al.: Phosphatidylinositol- 3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulinlike growth factor-1 in human hepatic stellate cells. J Hepatol 2000, 32:227–234.

    Article  PubMed  CAS  Google Scholar 

  27. Tangkijvanich P, Tam SP, Yee Jr HF: Wound induced migration of rat hepatic stellate cells is modulated by endothelin-1 through rho-kinase-mediated alterations in the acto-myosin cytoskeleton. Hepatology 2001, 33:74–80.

    Article  PubMed  CAS  Google Scholar 

  28. Friedman SL, Arthur MJ: Reversing hepatic fibrosis. Sci Med 2002, 8:194–205.

    CAS  Google Scholar 

  29. Sohara N, Znoyko I, Levy MT, et al.: Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J Hepatol 2002, 37:214–221.

    Article  PubMed  CAS  Google Scholar 

  30. Friedman SL: Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004, 1:98–105. Reviews mechanisms of liver fibrosis diagnosis and treatment.

    Article  PubMed  Google Scholar 

  31. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, AND DOSVIRC groups. Lancet 1997, 349:825–832.

    Article  PubMed  CAS  Google Scholar 

  32. Poynard T, Ratziu V, Charlotte F, et al.: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730–739.

    Article  PubMed  CAS  Google Scholar 

  33. Angelucci E, Muretto P, Nicolucci A, et al.: Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002, 100:17–21.

    Article  PubMed  CAS  Google Scholar 

  34. Lagging LM, Westin J, Svensson E, et al.: Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002, 22:136–144.

    Article  PubMed  Google Scholar 

  35. Schuppan D, Krebs A, Bauer M, Hahn EG: Hepatitis C and liver fibrosis. Cell Death Differ 2003, 10(suppl_1):S59-S67.

    Article  PubMed  CAS  Google Scholar 

  36. Guido M, Rugge M, Chemello L: Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J Hepatol 1996, 24:301–307.

    Article  PubMed  CAS  Google Scholar 

  37. Khan MA, Poulos JE, Brunt EM: Hepatic alfa smooth muscle actin expression in hepatitis C patients before and after interferon therapy. Hepatogastroenterology 2001, 48:212–215.

    Article  PubMed  CAS  Google Scholar 

  38. Sakaida I, Nagatomi A, Hironaka K: Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am J Gastroenterol 1999, 94:489–496.

    Article  PubMed  CAS  Google Scholar 

  39. Martinelli ALC, Ramalho LNZ, Zucoloto S: Hepatic stellate cells in hepatitis C patients. Relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol 2004, 19:91–98.

    Article  PubMed  Google Scholar 

  40. Powell EE, Edwards-Smith CJ, Hay JL, et al.: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828–833.

    Article  PubMed  CAS  Google Scholar 

  41. Muhlbuaer M, Bosserhoff AK, Hartmann A, et al.: A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003, 125:1085–1093.

    Article  Google Scholar 

  42. Garcia-Trevijano ER, Iraburu MJ, Fontana L, et al.: Transforming growth factor beta1 induces the expression of alpha1(1) procollagen mRNA by a hydrogen peroxide-C/ EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 1999, 29:960–970.

    Article  PubMed  CAS  Google Scholar 

  43. Bataller R, Paik YH, Lindquist JN, et al.: Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004, 126:529–540.

    Article  PubMed  CAS  Google Scholar 

  44. Mazzocca A, Cappadona Sciammetta S, Carloni V, et al.: Binding of hepatitis C virus envelope protein E2 to CD81 upregulates MMP-2 in human hepatic stellate cells. J Biol Chem 2005, 280:11329–11339.

    Article  PubMed  CAS  Google Scholar 

  45. Rockey DC, Chung JJ: Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 1994, 42:660–670.

    PubMed  CAS  Google Scholar 

  46. Ueki T, Kaneda Y, Tsutsui H, et al.: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999, 5:226–230.

    Article  PubMed  CAS  Google Scholar 

  47. Galli A, Crabb DW, Ceni E, et al.: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002, 122:1924–1940.

    Article  PubMed  CAS  Google Scholar 

  48. Kon K, Ikejima K, Hirose M, et al.: Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002, 291:55–61.

    Article  PubMed  CAS  Google Scholar 

  49. Marra F, Efsen E, Romanelli RG, et al.: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119:466–478.

    Article  PubMed  CAS  Google Scholar 

  50. Houglum K, Venkataramani A, Lyche K, Chojkier M: A pilot study of the effects of D-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069–1073.

    Article  PubMed  CAS  Google Scholar 

  51. Shimizu I, Ma YR, Mizobuchi Y, et al.: Effects of Shosaiko- to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999, 29:282–284.

    Article  Google Scholar 

  52. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myelogenous leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042.

    Article  PubMed  CAS  Google Scholar 

  53. Okuno M, Moriwaki H, Muto Y, et al.: Protease inhibitors suppress TGF-beta generation by hepatic stellate cells. J Hepatol 1998, 29:1031–1032.

    Article  PubMed  CAS  Google Scholar 

  54. Nakamura T, Sakata R, Ueno T, et al.: Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine- treated rats. Hepatology 2000, 32:247–255.

    Article  PubMed  CAS  Google Scholar 

  55. George J, Roulot D, Koteliansky VE, et al.: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999, 96:12719–12724.

    Article  PubMed  CAS  Google Scholar 

  56. Ueki T, Kaneda Y, Tsutsui H, et al.: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999, 5:226–230.

    Article  PubMed  CAS  Google Scholar 

  57. Yu Q, Shao R, Qian HS, et al.: Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000, 105:741–748.

    Article  PubMed  CAS  Google Scholar 

  58. Arthur MJ, Mann DA, Iredale JP: Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 1998, 13(suppl):S33-S38.

    PubMed  CAS  Google Scholar 

  59. Salgado S, Garcia J, Vera J, et al.: Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000, 2:545–551.

    Article  PubMed  CAS  Google Scholar 

  60. Wright MC, Issa R, Smart DE, et al.: Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterol 2001, 121:685–698.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Liver Diseases, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, 10029, New York, NY, USA

    Scott L. Friedman MD

Authors
  1. Efsevia Albanis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott L. Friedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott L. Friedman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Albanis, E., Friedman, S.L. Antifibrotic targets and therapy in HCV. Curr hepatitis rep 5, 94–100 (2006). https://doi.org/10.1007/s11901-006-0011-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-006-0011-2

Keywords

Search

Navigation